Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults
Clinical trial NCT05272605 · COMPLETED
Trial details
- NCT number
- NCT05272605
- Sponsor
- University of Melbourne
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-05
- Primary completion
- 2023-04-19
- Enrollment
- 76
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.